Arbutus Biopharma Corp Business Acquisition, Pro Forma Net Income (Loss)
Arbutus Biopharma Corp (ABUS) reported Business Acquisition, Pro Forma Net Income (Loss) of -$67.42 million for the 12-month period ending 2015-12-31, per its 10-K filed 2016-03-09.
Discontinued › Expense Statement › Operating Expenses
us-gaap:BusinessAcquisitionsProFormaNetIncomeLoss · last filed 2016-03-09
- Arbutus Biopharma Corp business acquisition, pro forma net income (loss) for fiscal 2015 was -$67.42M.
- Arbutus Biopharma Corp business acquisition, pro forma net income (loss) for fiscal 2014 was -$56.49M.
| Period end | Business Acquisition, Pro Forma Net Income (Loss) 12 month |
|---|---|
| 2015-12-31 | -$67.42M 10-K · filed 2016-03-09 |
| 2014-12-31 | -$56.49M 10-K · filed 2016-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |